STOCK TITAN

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Syndax Pharmaceuticals announced management will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on January 27, 2022, at 12:00 p.m. ET. The event will be accessible via a live webcast on the Investor section of the Company's website, with a replay available for a limited time. Syndax is focused on developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat. For detailed information, visit www.syndax.com.

Loading...
Loading translation...

Positive

  • Participation in a notable oncology conference may enhance visibility and interest in the company and its pipeline.
  • The presence of management at the conference could indicate confidence in the company's development efforts.

Negative

  • None.
Argus Session date unavailable
+1.39% session move Open Argus
Details

News Market Reaction – SNDX

The recorded move for SNDX in the trading session of this news was +1.39%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com 
Tel 862.368.4464

SNDX-G

Cision View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-b-riley-securities-2022-oncology-conference-301464483.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event will Syndax Pharmaceuticals present at?

Syndax Pharmaceuticals will present at B. Riley Securities' 2022 Oncology Conference on January 27, 2022.

What is the date and time of Syndax's fireside chat?

The fireside chat will be on January 27, 2022, at 12:00 p.m. ET.

How can I access the webcast of Syndax's presentation?

The webcast can be accessed from the Investor section of Syndax's website.

What are some of the therapies in Syndax's pipeline?

Syndax's pipeline includes SNDX-5613, axatilimab, and entinostat.

Keep reading